Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corporation reporting person Daniel J. Lippis filed a notice of proposed sale of common stock in connection with an employee stock option exercise, with broker payment for a cashless exercise expected on 08/11/2026. The notice references trading on the NYSE and includes issuer information for Edwards Lifesciences and Charles Schwab & Co., Inc. as broker.
The filing lists prior sales of Edwards Lifesciences common stock over the past three months by Daniel J. Lippis, including transactions on 05/18/2026, 06/30/2026, and 07/10/2026, each with specified share amounts and dollar values.
Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported selling 146.3127 shares of Common Stock on July 30, 2026, in a sale described as an open-market or private transaction at $86.0338 per share. After this sale, he directly holds 21533.5581 shares. The transaction was not designated as pursuant to a Rule 10b5-1 trading plan.
Edwards Lifesciences Corp. received a Form 144 notice relating to a proposed sale of up to 50,000 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value of $4,625,000.00, expected on or about 07/30/2026 on the NYSE.
The shares are tied to equity compensation awards designated as RSU / PSU dated 02/20/2018. During the past three months, a separate transaction reported the sale of 64,152 shares for $5,555,061.00 on 05/29/2026. Shares outstanding were 575,800,000, a baseline figure, not the amount being offered.
Wayne Markowitz, associated with Edwards Lifesciences Corp (EW), filed a notice of intent to sell common stock. Recent sale history shows transactions of 593 shares for $47,280.00 on May 11, 2026, and 9,628 shares for $818,958.00 on July 28, 2026.
Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences, exercised employee stock options covering 9,628 shares of common stock at $74.02 per share on July 28, 2026, then sold 9,628 shares at $85.06 per share the same day. Following the exercise, 9,628 derivative option securities are reported as held.
Edwards Lifesciences Corporation is the issuer for a planned resale of its common stock disclosed by shareholder Wayne Markowitz. The notice covers up to 818,958 shares of common stock to be sold through broker Charles Schwab & Co., Inc., with the stock listed on the NYSE. The company reports 575,800,000 shares outstanding of this class as of the notice. The planned transaction is associated with an employee stock option exercise and a broker payment for a cashless exercise. During the prior three months, a separate sale of 593 shares occurred on May 11, 2026 for total proceeds of $47,280.
Edwards Lifesciences Corp CEO Bernard J. Zovighian reported several Common Stock transactions dated July 27, 2026. He made bona fide gifts totaling 639.2998 shares, moving 319.6499 shares out of direct ownership and 319.6499 shares into a trust, while an affiliated trust sold 2,920.5511 shares at $83.9342 per share. Following these changes, he directly held 98,845 shares, with an additional 3,733.5603 shares held indirectly through a 401(k).
Edwards Lifesciences Corporation insider Bernard J. Zovighian filed a notice of proposed disposition of common stock under Form 144, naming Charles Schwab & Co., Inc. as broker. The filing also lists prior sales of 36,351 shares for $2,833,013.00 on May 12, 2026 and 523 shares for $45,982.00 on June 17, 2026.
Edwards Lifesciences reported strong second quarter 2026 results, with net sales of $1.74 billion, up 13.6% year over year (constant currency growth 12.5%). Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.26 billion, up 11.3%, Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were $195.9 million, up 47.3%, and Surgical sales were $284.1 million, up 6.5%. GAAP diluted EPS was $0.42, while adjusted EPS was $0.78. Gross margin was 77.5% and operating margin 29.5% (30.0% adjusted).
Results included a $40.0 million impairment charge and a $188.2 million valuation allowance tied to a California R&D tax credit law change, driving an effective tax rate of 53.6% and lower GAAP EPS versus $0.57 a year earlier. Cash and cash equivalents were about $2.9 billion, with total debt near $600 million and $1.5 billion remaining under the share repurchase authorization.
Based on this performance, Edwards raised 2026 constant currency sales growth guidance to 10%–11%, TAVR growth to 8%–9%, and TMTT sales guidance to $760–$780 million, now expecting total 2026 sales of $6.6–$6.9 billion and TAVR sales of $4.75–$5.0 billion. Adjusted EPS guidance of $2.95–$3.05 was reaffirmed. For Q3 2026, projected sales are $1.63–$1.71 billion, with adjusted EPS of $0.71–$0.77.